Reata Pharmaceuticals Overview

  • Year Founded
  • 2002

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 323

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $6.61B

Reata Pharmaceuticals General Information

Description

Developer of oral anti-inflammatory drugs intended for the treatment of serious and life-threatening diseases. The company focuses on identifying, developing, and commercializing therapeutics to address serious and life-threatening diseases by targeting molecular pathways.

Contact Information

Formerly Known As
Reata Discovery
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 5320 Legacy Drive
  • Plano, TX 75024
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
Vertical(s)
Corporate Office
  • 5320 Legacy Drive
  • Plano, TX 75024
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Reata Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
15. Merger/Acquisition 26-Sep-2023 $6.61B Completed Generating Revenue
14. Debt - General 01-May-2023 Completed Generating Revenue
13. PIPE 24-Jun-2020 Completed Generating Revenue
12. 2PO 14-Nov-2019 Completed Generating Revenue
11. 2PO 06-Dec-2016 Cancelled Generating Revenue
10. Debt - General 03-Apr-2017 Completed Generating Revenue
9. IPO 26-May-2016 Completed Generating Revenue
8. Later Stage VC (Series H) 13-Jul-2011 Completed Generating Revenue
7. Later Stage VC (Series G) 28-Sep-2009 $78M $176M Completed Generating Revenue
6. Later Stage VC (Series F) 04-Dec-2008 $32M $98.4M Completed Generating Revenue
To view Reata Pharmaceuticals’s complete valuation and funding history, request access »

Reata Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series H
Series G2
Series G1
Series F
Series E
Series D
Series C
Series B 3,331,247 $0.001000 $0.12 $1.5 $1.5 1x $1.5 3.4%
Series A 1,751,000 $0.001000 $0.08 $1 $1 1x $1 1.79%
To view Reata Pharmaceuticals’s complete cap table history, request access »

Reata Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of oral anti-inflammatory drugs intended for the treatment of serious and life-threatening diseases. The compa
Drug Discovery
Plano, TX
323 As of 2022

San Diego, CA
 

Cambridge, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Reata Pharmaceuticals Competitors (76)

One of Reata Pharmaceuticals’s 76 competitors is Crinetics Pharmaceuticals, a Formerly VC-backed company based in San Diego, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Crinetics Pharmaceuticals Formerly VC-backed San Diego, CA
Sarepta Therapeutics Formerly VC-backed Cambridge, MA
Pharmacyclics Venture Capital-Backed San Francisco, CA
etherna Formerly VC-backed Niel, Belgium
Intellia Therapeutics Formerly VC-backed Cambridge, MA
You’re viewing 5 of 76 competitors. Get the full list »

Reata Pharmaceuticals Patents

Reata Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2022208727-A1 Synthetic ursolic acid derivatives and methods of use thereof Inactive 18-Jan-2021
CA-3204434-A1 Synthetic ursolic acid derivatives and methods of use thereof Pending 18-Jan-2021
EP-4277916-A1 Synthetic ursolic acid derivatives and methods of use thereof Pending 18-Jan-2021
US-20240140986-A1 Synthetic ursolic acid derivatives and methods of use thereof Pending 18-Jan-2021
WO-2022155614-A1 Synthetic ursolic acid derivatives and methods of use thereof Inactive 18-Jan-2021 C07J63/008
To view Reata Pharmaceuticals’s complete patent history, request access »

Reata Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Reata Pharmaceuticals Former Investors (16)

Investor Name Investor Type Holding Investor Since Participating Rounds
AbbVie Corporation Majority
AbbVie Ventures Corporate Venture Capital Minority
Blackstone PE/Buyout Minority
Blackstone Life Sciences Other Private Equity Minority
CIC Partners PE/Buyout Minority
You’re viewing 5 of 16 investors. Get the full list »

Reata Pharmaceuticals ESG

Risk Overview

Risk Rating

Updated December, 31, 2023

25.99 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,766

Rank

Percentile

Pharmaceuticals

Industry

of 891

Rank

Percentile

Biotechnology

Subindustry

of 394

Rank

Percentile

To view Reata Pharmaceuticals’s complete esg history, request access »

Reata Pharmaceuticals Affiliates

Subsidiaries (2)

Name Industry Location Year Founded
Reata Pharmaceuticals Global Cambridge, MA 2020
Reata Pharmaceuticals Holdings Plano, TX

Reata Pharmaceuticals FAQs

  • When was Reata Pharmaceuticals founded?

    Reata Pharmaceuticals was founded in 2002.

  • Where is Reata Pharmaceuticals headquartered?

    Reata Pharmaceuticals is headquartered in Plano, TX.

  • What is the size of Reata Pharmaceuticals?

    Reata Pharmaceuticals has 323 total employees.

  • What industry is Reata Pharmaceuticals in?

    Reata Pharmaceuticals’s primary industry is Drug Discovery.

  • Is Reata Pharmaceuticals a private or public company?

    Reata Pharmaceuticals is a Private company.

  • What is the current valuation of Reata Pharmaceuticals?

    The current valuation of Reata Pharmaceuticals is .

  • What is Reata Pharmaceuticals’s current revenue?

    The current revenue for Reata Pharmaceuticals is .

  • How much funding has Reata Pharmaceuticals raised over time?

    Reata Pharmaceuticals has raised $1.64B.

  • Who are Reata Pharmaceuticals’s investors?

    AbbVie, AbbVie Ventures, Blackstone, Blackstone Life Sciences, and CIC Partners are 5 of 16 investors who have invested in Reata Pharmaceuticals.

  • Who are Reata Pharmaceuticals’s competitors?

    Crinetics Pharmaceuticals, Sarepta Therapeutics, Pharmacyclics, etherna, and Intellia Therapeutics are some of the 76 competitors of Reata Pharmaceuticals.

  • When was Reata Pharmaceuticals acquired?

    Reata Pharmaceuticals was acquired on 26-Sep-2023.

  • Who acquired Reata Pharmaceuticals?

    Reata Pharmaceuticals was acquired by Biogen.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process